Source:http://linkedlifedata.com/resource/pubmed/id/15907448
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
3
|
pubmed:dateCreated |
2005-5-23
|
pubmed:abstractText |
In the present study, we evaluated the immunopotentiating efficacy of tuftsin against experimental murine aspergillosis in both normal and immunodebilitant BALB/c mice. The animals were challenged with an isolate of Aspergillus fumigatus (1x10(8) cfu/mouse) that was showing less susceptibility to lower doses of amphotericin B in murine animal model. Co-administration of the immunomodulator tuftsin and liposomised-amphotericin B was found to be highly effective in the treatment of systemic infection of A. fumigatus in both immunocompetent and leukopenic mice. Moreover, pre-treatment of mice with liposomised-tuftsin prior to challenging them with A. fumigatus infection and subsequent treatment with tuftsin-bearing liposomised-amphotericin B was found to be extremely efficient in successful elimination of fungal pathogen. In another set of experiments, tuftsin-mediated antigen-specific memory antibody response was also assessed by immunizing the animals with A. fumigatus cytosolic antigen. The animals that received a booster 150 days after the first immunization with tuftsin-liposomes-antigen showed more resistance to A. fumigatus infection in comparison with the naïve animals.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Amphotericin B,
http://linkedlifedata.com/resource/pubmed/chemical/Antifungal Agents,
http://linkedlifedata.com/resource/pubmed/chemical/Immunologic Factors,
http://linkedlifedata.com/resource/pubmed/chemical/Liposomes,
http://linkedlifedata.com/resource/pubmed/chemical/Tuftsin
|
pubmed:status |
MEDLINE
|
pubmed:month |
Jun
|
pubmed:issn |
0928-8244
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:day |
1
|
pubmed:volume |
44
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
269-76
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15907448-Amphotericin B,
pubmed-meshheading:15907448-Animals,
pubmed-meshheading:15907448-Antifungal Agents,
pubmed-meshheading:15907448-Aspergillosis,
pubmed-meshheading:15907448-Aspergillus fumigatus,
pubmed-meshheading:15907448-Drug Evaluation, Preclinical,
pubmed-meshheading:15907448-Drug Therapy, Combination,
pubmed-meshheading:15907448-Immunocompromised Host,
pubmed-meshheading:15907448-Immunologic Factors,
pubmed-meshheading:15907448-Liposomes,
pubmed-meshheading:15907448-Mice,
pubmed-meshheading:15907448-Mice, Inbred BALB C,
pubmed-meshheading:15907448-Microbial Sensitivity Tests,
pubmed-meshheading:15907448-Tuftsin
|
pubmed:year |
2005
|
pubmed:articleTitle |
Tuftsin-mediated immunoprophylaxis against an isolate of Aspergillus fumigatus shows less in vivo susceptibility to amphotericin B.
|
pubmed:affiliation |
Interdisciplinary Biotechnology Unit, Aligarh Muslim University, Aligarh 202002, India; Central Drug Research Institute, Lucknow, India.
|
pubmed:publicationType |
Journal Article,
Comparative Study
|